Cloudbreak Announces Final Patient Completes Endpoint Visit Of Phase 3 CBT-001 For Pterygium

Cloudbreak Pharma said its final patient in the phase 3 CBT-001 trial for pterygium has completed the 12-month endpoint visit. The update indicates trial progression is nearing completion, but it does not include efficacy, safety, or regulatory results. The news is factual and likely a routine development with limited near-term market impact.

Analysis

Cloudbreak Pharma said its final patient in the phase 3 CBT-001 trial for pterygium has completed the 12-month endpoint visit. The update indicates trial progression is nearing completion, but it does not include efficacy, safety, or regulatory results. The news is factual and likely a routine development with limited near-term market impact.